BiotechTube

dabigatran, rivaroxaban, apixaban or edoxaban

Pre-clinicalUNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atrial Fibrillation

Conditions

Atrial Fibrillation, Recurrent Venous Thromboembolism

Trial Timeline

Jul 29, 2019 → Aug 1, 2024

NCT ID
NCT04042155

About dabigatran, rivaroxaban, apixaban or edoxaban

dabigatran, rivaroxaban, apixaban or edoxaban is a pre-clinical stage product being developed by Daiichi Sankyo for Atrial Fibrillation. The current trial status is unknown. This product is registered under clinical trial identifier NCT04042155. Target conditions include Atrial Fibrillation, Recurrent Venous Thromboembolism.

What happened to similar drugs?

20 of 20 similar drugs in Atrial Fibrillation were approved

Approved (20) Terminated (4) Active (0)
✅OAC aloneDaiichi SankyoApproved
✅EdoxabanDaiichi SankyoApproved
✅Edoxaban + Aspirin and Clopidogrel + Aspirin and WarfarinDaiichi SankyoApproved
✅dapagliflozin + PlaceboAstraZenecaApproved
✅valsartanNovartisApproved
✅Apixaban + Parenteral heparin and/or oral Vitamin K antagonistPfizerApproved
✅Vitamin K antagonist + ApixabanPfizerApproved

Hype Score Breakdown

Clinical
3
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04042155Pre-clinicalUNKNOWN

Competing Products

20 competing products in Atrial Fibrillation

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
26
Edoxaban + Clopidogrel + Prasugrel + Ticagrelor + Vitamin K antagonistDaiichi SankyoPhase 3
40
OAC aloneDaiichi SankyoApproved
43
Edoxaban + ASADaiichi SankyoPhase 3
32
DU-176b tablets + DU-176b tablets + Warfarin tabletsDaiichi SankyoPhase 2
35
Edoxaban + Apixaban + RivaroxabanDaiichi SankyoPre-clinical
26
Edoxaban + VKA-Based Regimen + VKA-Based Regimen + VKA-Based Regimen + VKA-Based RegimenDaiichi SankyoPhase 3
40
Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + warfarinDaiichi SankyoPhase 2
35
EdoxabanDaiichi SankyoPre-clinical
26
EdoxabanDaiichi SankyoApproved
43
Edoxaban + Warfarin + EnoxaparinDaiichi SankyoPhase 3
40
EdoxabanDaiichi SankyoPre-clinical
26
EdoxabanDaiichi SankyoPre-clinical
26
DU-176b 15mg + DU-176b 30mg + DU-176b 60mgDaiichi SankyoPhase 3
40
EdoxabanDaiichi SankyoPre-clinical
26
DU-176b tablets + Warfarin potassium tabletsDaiichi SankyoPhase 2
35
Edoxaban-based Regimen + VKA-based RegimenDaiichi SankyoPhase 3
40
EdoxabanDaiichi SankyoPre-clinical
26
Edoxaban + Aspirin and Clopidogrel + Aspirin and WarfarinDaiichi SankyoApproved
39
EdoxabanDaiichi SankyoPre-clinical
26